RHHVF

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Roche Holding AG

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
CEO
Severin Schwan
Employees
0
Headquarters

Grenzacherstrasse 124
Basel, Basel-Stadt (Basle
Phone: 41.61.688.11.11
http://www.roche.com

News

Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Aug 07, 2024 15:25pm

Roche Holding AG (OTC: RHHBY ) is reportedly contemplating the divestiture of Flatiron Health , a cancer data specialist Roche acquired in 2018 for $1.9 billion. The move underscores the complexities and potential pitfalls that large pharmaceutical companies encounter when investing in early-stage health technology firms. Also Read: Roche’s New Immunotherapy Fails To Show Benefit Over Merck’s Blockbuster Keytruda In Lung Cancer Patients . Flatiron Health was founded by two former executives from Alphabet Inc’s (NASDAQ: GOOG ) (NASDAQ: GOOGL ) Google. The company manages electronic patient records for numerous U.S. cancer clinics, boasting one of the most extensive repositories of cancer data. The start-up mines this data and sells it to … Full story available on Benzinga.com


Source:Benzinga
Roche evaluating selling cancer startup Flatiron Health
Aug 07, 2024 13:22pm

No summary available.


Source:Seeking Alpha
Eli Lilly and Novo Nordisk face new competition in slimming drugs market
Aug 07, 2024 12:02pm

… US pharmaceuticals firm Eli Lilly and Danish Novo Nordisk in the slimming drugs market … is threatened. Two firms, Viking Therapeutics and Roche , announced … estimates the market for such drugs will grow from €14 billion …


Source:EIN News Pharmaceuticals
Roche considering divesting $1.9 billion cancer data startup: report
Aug 07, 2024 11:05am

Roche had paid $1.9 billion for New-York based Flatiron Health in 2018 to speed its development of cancer medicines and support its efforts to price them based on how well they work.


Source:Economic Times India
Roche considering divesting $1.9 billion cancer data startup, FT reports
Aug 07, 2024 04:20am

https://www.investing.com/news/stock-market-news/roche-considering-divesting-19-billion-cancer-data-startup-ft-reports-3558321


Source:Investing.com
Roche strikes new deal with Sangamo to tackle Alzheimer''s
Aug 07, 2024 00:48am

Swiss pharmaceutical giant Roche Holding AG has inked … Tuesday through Roche ’s Genentech research arm. Roche has licensed … diseases. This agreement grants Roche exclusive rights to molecules … Alzheimer’s disease. Additionally, Roche has secured rights to …


Source:EIN News Pharmaceuticals
Roche, Sangamo ink licensing deal for neuro drugs
Aug 06, 2024 13:03pm

No summary available.


Source:Seeking Alpha
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
Aug 06, 2024 12:05pm

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Sangamo has granted Genentech an exclusive license to Sangamo’s proprietary zinc finger repressors that are directed to the Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Roche shares target increased by Berenberg on Carmot acquisition impact
Aug 06, 2024 07:45am

https://www.investing.com/news/company-news/roche-shares-target-increased-by-berenberg-on-carmot-acquisition-impact-93CH-3556097


Source:Investing.com
New anti-obesity pills threaten Eli Lilly and Novo Nordisk’s stock market empire
Aug 04, 2024 04:21am

… Eli Lilly and Novo Nordisk on the stock market. The two pharmaceutical … producing and marketing anti-obesity drugs . However, this is a … risen by 235%. Similarly, Roche — which had previously announced … facing Novo Nordisk and Eli Lilly was meeting the huge …


Source:EIN News Pharmaceuticals